Kandi Technologies Group, Inc. announced two new executive appointments to help support its continuing rapid growth. Kandi's board of directors has appointed Mr. Wang Cheng (Henry) as the company's new Chief Strategy Officer and Mr. Mei Bing as the company's Chief Financial Officer, with both appointments effective immediately. Mr. Wang, who is resigning as its Chief Financial Officer in order to assume the position of Chief Strategy Officer, has 20 years of experience in operations, strategy, financial management, and mergers and acquisitions.

Going forward, he will be responsible for driving Kandi's corporate strategy and implementing investment decisions. Mr. Mei is a seasoned financial executive with a distinguished career of more than 15 years as an executive with Fortune 500 companies, large multinational enterprises, and middle market companies, including public companies, in both the U.S. and China. Before joining Kandi, Mr. Mei served as the Chief Financial Officer and board secretary of Skystar Bio-Pharmaceutical Company, a leading publicly traded biotechnology company based in China, from 2011 through 2016.

From 2015 through 2016, he also served as an independent non-executive member of the board of directors and as chairman of the audit committee of PharmaMax Corporation, also based in China. From 2006 through 2011, Mr. Mei served as the Chief Financial Officer of Avineon, Inc., where he managed the Company's global financial operations in North America, Asia and Europe. Prior to his service Avineon, Inc., he served as Controller of Arrowhead Global Solutions, Inc.